Objective: KIAA1199 has been identified as an oncogene in many cancers. Here we collected tissues of 153 of Non-Small Cell Lung Cancer (NSCLC) cases to investigate the relationships between KIAA1199 protein and clinical factors.
Methods: Immunohistochemistry (IHC) staining was used to detect the expression of KIAA1199. Follow-up was carried out every 3 months for the first 2 y and at 6-month intervals thereafter during the follow-up period (3 y), which include included blood analysis, chest X-ray, ultrasound examination, computed tomography. Kaplan-Meier survival analysis and Cox analysis were applied to identify the relationship between KIAA1199 and NSCLC.
Results: IHC results showed that 76 (49.67%) specimens had strong expression of KIAA1199 protein, with poor differentiation (P=0.003), higher positive lymph node metastasis (P=0.001), and higher Tumor Node Metastasis (TNM) stage (P=0.016). Kaplan-Meier survival analysis revealed that patients with high expression of KIAA1199 protein had poor overall survival (OS; P=0.004). Cox analysis suggested that the KIAA1199 protein was an independent prognostic marker for NSCLC patients (P=0.040).
Conclusion: Our findings revealed that KIAA1199 protein could be applied in predicting NSCLC patient’s outcome.